Our data thereby revealed that CARM1 is required for estrogen/ERα-induced transcriptional activation, breast cancer cell growth and tumorigenesis, suggesting CARM1 might serve as a potential drug target in ERα-positive and endocrine therapy-resistant breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.